Budoprutug
As of the edition of 20 October 2026, Budoprutug is an antibody: in active development; acts on CD19.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 8, 3 stopped early
- Disease areas
- Immune system; Pregnancy and women's health; Skin and connective tissue; Urinary and reproductive; Blood and lymph
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Budoprutug.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD19 | B-lymphocyte antigen CD19 | P15391 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 1 | 0 |
| Phase 2 | 6 | 0 | 3 | 3 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Tenet Medicines | Lead sponsor of trials | 2021 to now |
| Climb Bio | Lead sponsor of trials | 2025 to now |